Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 5/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78780 | 0.87 | ALDH1A1 (0.51) | ALDH1A1GAAHTTMRGPRX4ACACB | |
| SCHEMBL13464023 | 0.81 | ALDH1A1 (0.42) | ALDH1A1GAAHTTMRGPRX4PTGDR2 | |
| SCHEMBL4057890 | 0.81 | AR (0.48) | ALDH1A1GAAHTTAR | |
| SCHEMBL31568536 | 0.77 | PDE2A (0.44) | ALDH1A1GAAHTTMRGPRX4ACACB | |
| SCHEMBL15541043 | 0.77 | PDE2A (0.44) | ALDH1A1GAAHTTMRGPRX4ACACB | |
| SCHEMBL20595717 | 0.77 | PGK1 (0.43) | ALDH1A1GAAHTTPTGDR2PGK1 | |
| SCHEMBL18586815 | 0.77 | ALDH1A1 (0.41) | ALDH1A1GAAHTTMRGPRX4PTGDR2 | |
| SCHEMBL3860645 | 0.75 | MRGPRX4 (0.56) | ALDH1A1GAAMRGPRX4ACACBPTGDR2 | |
| SCHEMBL3870663 | 0.75 | MRGPRX4 (0.53) | ALDH1A1MRGPRX4ACACBPTGDR2PDE2A | |
| Hydrochloric Acid SCHEMBL3870669 | 0.74 | MRGPRX4 (0.55) | ALDH1A1GAAMRGPRX4ACACBPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | ALDH1A1 646/4885GAA 1918/4885HTT 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.